Nentwich Martin M, Ulbig Michael W
Martin M Nentwich, Michael W Ulbig, Department of Ophthalmology, Ludwig-Maximilians University, 80336 Munich, Germany.
World J Diabetes. 2015 Apr 15;6(3):489-99. doi: 10.4239/wjd.v6.i3.489.
In industrialized nations diabetic retinopathy is the most frequent microvascular complication of diabetes mellitus and the most common cause of blindness in the working-age population. In the next 15 years, the number of patients suffering from diabetes mellitus is expected to increase significantly. By the year 2030, about 440 million people in the age-group 20-79 years are estimated to be suffering from diabetes mellitus worldwide (prevalence 7.7%), while in 2010 there were 285 million people with diabetes mellitus (prevalence 6.4%). This accounts for an increase in patients with diabetes in industrialized nations by 20% and in developing countries by 69% until the year 2030. Due to the expected rise in diabetic patients, the need for ophthalmic care of patients (i.e., exams and treatments) will also increase and represents a challenge for eye-care providers. Development of optimized screening programs, which respect available resources of the ophthalmic infrastructure, will become even more important. Main reasons for loss of vision in patients with diabetes mellitus are diabetic macular edema and proliferative diabetic retinopathy. Incidence or progression of these potentially blinding complications can be greatly reduced by adequate control of blood glucose and blood pressure levels. Additionally, regular ophthalmic exams are mandatory for detecting ocular complications and initiating treatments such as laser photocoagulation in case of clinical significant diabetic macular edema or early proliferative diabetic retinopathy. In this way, the risk of blindness can considerably be reduced. In advanced stages of diabetic retinopathy, pars-plana vitrectomy is performed to treat vitreous hemorrhage and tractional retinal detachment. In recent years, the advent of intravitreal medication has improved therapeutic options for patients with advanced diabetic macular edema.
在工业化国家,糖尿病视网膜病变是糖尿病最常见的微血管并发症,也是劳动年龄人口失明的最常见原因。在未来15年,预计糖尿病患者数量将显著增加。到2030年,估计全球20 - 79岁年龄段约有4.4亿人患有糖尿病(患病率7.7%),而2010年有2.85亿糖尿病患者(患病率6.4%)。到2030年,工业化国家糖尿病患者数量将增加20%,发展中国家将增加69%。由于糖尿病患者预计会增加,对患者眼科护理(即检查和治疗)的需求也将增加,这对眼科护理人员构成挑战。制定优化的筛查计划,考虑到眼科基础设施的可用资源,将变得更加重要。糖尿病患者视力丧失的主要原因是糖尿病性黄斑水肿和增殖性糖尿病视网膜病变。通过充分控制血糖和血压水平,这些潜在致盲并发症的发生率或进展可大大降低。此外,定期眼科检查对于检测眼部并发症以及在出现临床显著的糖尿病性黄斑水肿或早期增殖性糖尿病视网膜病变时启动激光光凝等治疗是必不可少的。通过这种方式,失明风险可大幅降低。在糖尿病视网膜病变的晚期,进行玻璃体切割术治疗玻璃体积血和牵拉性视网膜脱离。近年来,玻璃体内药物的出现改善了晚期糖尿病性黄斑水肿患者的治疗选择。